Telix Pharmaceuticals announces launch of Renal cancer imaging study
Category: #health  By Mateen Dalal  Date: 2019-08-31
  • share
  • Twitter
  • Facebook
  • LinkedIn

Telix Pharmaceuticals announces launch of Renal cancer imaging study
  • The pharmaceutical company declared the completion of CTN submission to Japanese PMDA for TLX250-CDx.
  • It is permitted to conduct Phase trials for renal cancer patients.

Australia based clinical-stage biopharmaceutical firm Telix Pharmaceuticals reportedly announced successful completion of a Clinical Trial Notification submission to the Japanese Pharmaceutical & Medical Devices Agency for TLX250-CDx.

For the uninitiated, Telix Pharmaceuticals Limited, headquartered in Australia is a biopharmaceutical company working towards the development of diagnostic and therapeutic products dependent on radiopharmaceuticals.

Reportedly, the company’s owned subsidiary Telix Japan had submitted the CTN at the July end following a robust consultation process with the PMDA. It has been claimed that the company tried resolving the PMDA’s remaining questions whilst collaborating with the other major shareholders like the Ministry of Health, and Labour and Welfare (MHLW).

As per trusted reports, Telix is now allowed to initiate a study designed to extend the company’s global ZIRCON Phase 3 investigation. It has been claimed that the study would register over 40 renal cancer patients. The phase 2 is expected to grow to a multi-focus study whilst operating under a procedure that is considered to be accurately identical to the ZIRCON investigation.

Speaking on the trial, the President of Telix Japan, Dr. Shintaro Nishimura reportedly stated that the company believes that CTN would wholly transform the face of the Japanese Nuclear Medicine community accounting to its first formal clinical investigation for the zirconium PET imaging in Japan. Additionally, TLX250-CDx offers an incredible potential to offer benefits to the cancer patients which would eventually help make way for impending use of theranostics in the country.

Meanwhile, the CEO of the company, Dr, Christian Behrenbruch cited that Telix has introduced a major amount to effort to accomplish the study and make it function in the states of Japan along with manufacturing the radiopharmaceutical products domestically within confined governing environment. Furthermore, the company is grateful to its clinical and finance partners for their constant support and involvement.

Source credit: https://www.globenewswire.com/news-release/2019/08/30/1908793/0/en/Telix-Pharmaceuticals-to-Launch-Japanese-Renal-Cancer-Imaging-Study.html

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

PayPal buys Happy Returns to strengthen reverse logistics system
PayPal buys Happy Returns to strengthen reverse logistics system
By Mateen Dalal

U.S. based digital payments platform, PayPal, an online payment system entity has announced the purchase of Happy Returns- a returns solution firm that provides online buyers access to simplified ways to return unwanted merchandise to retailers; elim...

YOP officially unveils YOP app to ease access to DeFi for the masses
YOP officially unveils YOP app to ease access to DeFi for the masses
By Mateen Dalal

Yield Optimization Platform and Protocol (YOP) recently declared its official launch of YOP application; the first all-in-one mobile app which makes it quite easier for everyone to access DeFi. The V0 version of the app is now available for early acc...

Singapore to create second national supercomputer with more on roadmap
Singapore to create second national supercomputer with more on roadmap
By Mateen Dalal

Following its success of the first supercomputer system, Singapore is set to build its upcoming second supercomputer system in an attempt to strengthen the local research community, offering 8X more computing capacity than its previous model. The sy...